NeoMatrix Inc., an Irvine medical testing company, has raised $9.6 million in a third round of funding.
NeoMatrix said it’s going to use the money to expand sales of its Halo system, which is designed to test women for atypical ductal hyperplasia, a biomarker that can be a precursor to breast cancer.
The company didn’t disclose the investors in the round of funding.
It did say it added a pair of directors: Anthony Ciabattoni, an entrepreneur who serves as an advisor for Waveland Capital Group LLC of Irvine, an investment banking firm that raises capital for early-stage companies, including NeoMatrix; and Richard Franco, chief executive of Dara BioSciences Inc., a Raleigh, N.C. private drug development company.
